Merck's FDA Approval of Lipfendra and Strategic Moves Propel Stock to New Heights

Merck’s FDA Approval of Lipfendra and Strategic Moves Propel Stock to New Heights

On July 16, 2026, Merck & Co. (NYSE: MRK) achieved a significant milestone with the U.S. Food and Drug Administration’s approval of Lipfendra, the first oral PCSK9 inhibitor designed to lower LDL cholesterol levels. This approval marks a pivotal expansion of Merck’s cardiovascular portfolio and has been a key driver in the company’s recent stock performance.

FDA Approval of Lipfendra

Merck’s Lipfendra, also known as enlicitide, received FDA approval as a once-daily oral treatment for hypercholesterolemia, including hereditary forms of the disease. This approval is particularly noteworthy as Lipfendra is the first oral PCSK9 inhibitor to enter the market, offering a convenient alternative to existing injectable therapies. The approval underscores Merck’s commitment to addressing unmet needs in cardiovascular health and diversifying its product offerings beyond oncology.

Stock Performance and Market Reaction

Following the FDA approval, Merck’s stock experienced a notable uptick. On July 17, 2026, the stock reached a 52-week high of $130.34, reflecting a 62.01% increase over the past year. This surge indicates strong investor confidence in Merck’s strategic direction and its ability to deliver innovative treatments. As of July 17, 2026, Merck’s stock was trading at $127.50, with a slight decrease of 0.74% from the previous close, suggesting a period of consolidation after the recent gains.

Strategic Acquisition of Terns Pharmaceuticals

In addition to the Lipfendra approval, Merck has been actively expanding its oncology pipeline. On May 5, 2026, the company completed the acquisition of Terns Pharmaceuticals, Inc., adding TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, to its portfolio. This acquisition aligns with Merck’s strategy to diversify its therapeutic areas and strengthen its position in the oncology market.

Analyst Perspectives

Analysts have responded positively to Merck’s recent developments. HSBC analyst Rajesh Kumar raised the firm’s price target on Merck to $150 from $135, maintaining a Buy rating on the shares. This adjustment reflects optimism about Merck’s growth prospects, particularly in light of the Lipfendra approval and strategic acquisitions.

Conclusion

Merck’s recent FDA approval of Lipfendra and the strategic acquisition of Terns Pharmaceuticals have significantly bolstered the company’s market position and stock performance. These developments highlight Merck’s commitment to innovation and diversification, positioning the company for sustained growth in the competitive pharmaceutical landscape. Investors and stakeholders will be closely monitoring how these strategic moves translate into long-term financial performance and market share expansion.